Chronic Kidney Disease Trial, Recruiting NCT06089473 Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT06089473
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have end-stage kidney disease (kidneys that have stopped working) and have been assessed as pre-frail, frail, or very frail using a standard frailty measurement tool called Fried's Frailty Phenotype
  • People who are on, or in the process of being added to, the kidney transplant waiting list at one of three participating hospitals (McGill University Health Centre, Centre Hospitalier de l'Université de Montréal, or University of Alberta Hospital), whether for a first transplant or a repeat transplant
  • People who speak English or French
  • People who are able to join video calls online, either on their own or with help from someone in their household — people without internet access may be able to borrow a tablet for the duration of the study (confirm with trial site)

Who may not be able to join:

  • People who score as "robust" (not frail) on the Fried's Frailty Phenotype assessment
  • People who are already taking part in a structured exercise program, whether at a hospital, at home, or through another research trial
  • People who are waiting for a combined kidney-pancreas or kidney-liver transplant, as those waiting lists tend to be much longer
  • People who are currently in hospital for any reason at the time eligibility is being assessed
  • People with a very high level of antibody sensitisation (above 95% cPRA) who are on a special exchange program and expected to wait a long time for a transplant (confirm with trial site)
  • People who are expected to receive a transplant before the 12-week program is finished — for example, those receiving a kidney from a living donor or those with type A blood
  • People who have significant cognitive impairment (serious difficulties with memory or thinking), whether pre-existing or newly identified
  • People who have a pre-existing or newly identified heart condition, bone or joint condition, nerve condition, or neurological condition that could affect their ability to exercise safely

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Tania Janaudis-Ferreira, PhD, Research Institute of McGill University Health Centre (RI-MUHC)

Phone: 514-619-0871

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Registry
ClinicalTrials.gov
Start date
2 November 2024
Est. completion
1 August 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Proportion of screened patients who meet eligibility criteria; Proportion of eligible patients who consent to randomization; Proportion of patients who adhere to the interventions; Rate of follow-up completion as assessed by number of randomized patients completing assessments pre- and post-induction phase.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov